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Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell trans-
plantation (HCT) and the main cause of nonrelapse mortality during the ﬁrst 100 days post-transplant.
Although GVHD can be prevented by extensive removal of mature donor T cells from the donor hemato-
poietic stem cell population, doing so eliminates any potential allogeneic graft-versus-tumor (GVT) effect also
mediated by donor T cells and results in unacceptable rates of cancer relapse. One potential solution to this
problem of separating GVHD development from a GVT response is to prevent T cellemediated GVHD in the
intestinal tract (IT) while preserving systemic antihost alloreactivity of donor T cells that target residual tumor
cells expressing host alloantigens. We examined the ability of the anti-inﬂammatory rho kinase inhibitor,
fasudil, given orally and intraperitoneally, to prevent GVHD in a C3H / B6C3F1 mouse model of MHC-
haploidentical bone marrow transplantation. Fasudil-treated recipients of anti-thy-1 mAb þ C0 treated
bone marrow (ATBM) cells plus T cells had a 73% 90-day survival compared with 25% among untreated
ATBM þ T cell recipients (P < .0001). Severe initial weight loss was similar in the 2 groups, but less diarrhea
was observed among treated animals, and fasudil-treated survivors recovered more weight than untreated
survivors. Skin inﬂammation occurred and resolved between weeks 2 and 8 with similar severity and kinetics
in both treated and untreated surviving animals, indicating persistent alloreactivity. Day 10 post-
transplantation splenocytes from fasudil-treated mice, containing mature donor T cells, and day 98 spleno-
cytes, containing mature donor and de novo thymus-derived T cells, exhibited alloreactivity against host
parental antigens, as assessed by in vitro IFN-g production and rounds of allostimulated proliferation,
respectively. These data support the idea that targeted treatment of the IT with rho kinase inhibitors can
ameliorate lethal GVHD while preserving systemic alloreactivity. The results also suggest that similar
mechanisms of IT-speciﬁc tolerance or resistance to GVHD operate in fasudil-treated and untreated long-term
survivors of allogeneic ATBM þ T cells.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Althoughmultiple organs are typically involved, the main
cause of death in acute graft-versus-host disease (GVHD)
appears to be damage to the intestinal tract (IT), especially
the small and large bowel [1,2]. Whereas skin involvement is
more frequent, IT GVHD is more refractory to treatment and
more predictive of nonrelapse mortality (NRM) [3e5]. Pre-
vention of GVHD by purging donor hematopoietic cell
transplants (HCTs) of mature lymphocytes before trans-
plantation leads to untenable rates of tumor relapse because
of the loss of a graft-versus- tumor (GVT) effect, also medi-
ated by mature donor lymphocytes (primarily T cells).
Indeed, a roughly inverse correlation between severity of
GVHD and incidence of relapse has been documented [6e8].
This conundrum has spurred efforts to mitigate GVHD while
preserving a GVT effect.
One strategy is to identify tumor-speciﬁc antigens and the
T cell clones recognizing them so they can be selectivelyedgments on page 1110.
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[9,10]. The limited number of cancers with well-deﬁned tu-
mor-speciﬁc antigens is an obstacle to this approach, but so,
too, is the removal of alloreactivity, which comprises a much
broader, stronger, and less readily evaded tumor response
repertoire than that generated against a single tumor-
speciﬁc antigen. Another approach is to augment regulato-
ry T cells (Tregs) in the graft with additional donor Tregs;
however, like immunosuppression in general or removal of
mature donor T cells from the donor graft, this may carry the
risk of increased relapse [11].
A very different conceptual strategy is to ameliorate
GVHD in the most vulnerable organs while preserving
alloreactivity in general and an alloreactive GVT effect in
particular. The theoretical possibility of achieving this situ-
ation has been demonstrated in mouse models by use of
donor T cells genetically deﬁcient in receptors critical for gut
homing [2,12] or in cytotoxic T lymphocyte (CTL) synapse
formation [13]. More directly relevant to treatment, murine
GVHD has been suppressed by immunodepletion of T cells
expressing gut homing receptors from the transplant [12],
injection of mAb targeting neovascularizing donor endo-
thelial cells [14,15], or administration of inhibitors of T cell
receptorecoupled protein kinase C (PKC)a and PKCq proteinsTransplantation.
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ing (although, surprisingly, not eliminating) antitumor CTL.
By contrast, the homing receptorebased approaches appear
to reduce the inﬂux of inﬂammatory cells into the bowel
mucosa while leaving the remaining systemic alloimmunity
largely intact. This raises the possibility that alloreactive
T cells might be redirected to the skin and non-IT organs,
exacerbating morbidity and mortality from nondigestive
tract GVHD. Although this was not observed in the studies
just cited, there was some evidence of redirection of GVHD
away from gut and into skin in mice fed a vitamin
Aedeﬁcient diet leading to decreased CCR9 and a4b7
expression on lymphocytes [16].
Importantly, an approach that, despite its potential for
systemic immunosuppression, seems to target the IT has
recently been translated from animals to clinical studies. The
CCR5 blocking agent, maraviroc, given orally to patients from
e2 to þ30 days post-HCT, resulted in dramatically reduced
GVHD and NRM within the ﬁrst 100 days as well as 1 year
post-transplantation compared with historical control sub-
jects at the same institution [5]. In particular, there was a
NRM rate of 0% within the ﬁrst 100 days and no grade III or IV
IT or liver GVHD. CCR5 was ﬁrst shown to be important as a
marker of host-reactive T cells in mouse models of GVHD
targeting skin, liver, and gut tissues [17,18]. Thus, despite the
expression of CCR5 on alloreactive lymphocytes throughout
the body, gut-sparing effects appeared to dominate the
clinical results of this trial, accounting for most of the
beneﬁcial effects.
In light of the above studies, we took an approach with
anticipated systemic effects but also with the potential to
preferentially target the IT. We used a rho-associated coiled
coil kinase inhibitor, fasudil, demonstrated tohave suppressive
effects on inﬂammatorycell activation,motility, andhoming in
the context of preclinical models of autoimmune disease [19]
and tumor metastasis [20e28]. Although potentially sys-
temic in impact, we reasoned that p.o. and i.p. administration
might result in predominant protection of the IT because of
concentration gradients and initial local gut mucosal and
serosal uptake. Fasudil is of particular interest, because it has
an excellent 20-year safety record of use in Japan for preven-
tion of poststroke cerebral artery spasm [29,30].METHODS
Mice
Eight-week-old male C3H/HeJ (C3H; H2k), (C57BL/6  C3H)F1 (B6C3F1;
H2b/k), DBA/2J (H2d), and BALB/cJ (H2d) mice were obtained from the
Jackson Laboratory (Bar Harbor, ME) and used at 10 to 20 weeks as cell
recipients or donors. Mice were kept in a pathogen-free environment in
autoclaved microisolator cages and were provided with autoclaved water
and food ad libitum. All protocols used in this study were approved by the
Hackensack University Medical Center’s Institutional Animal Care and Use
Committee.Transplantation Experiments
All preparative manipulations of donor cells were conducted in PBS
supplemented with .1% bovine BSA. T celledepleted (anti-thy-1 mAb-
treated) bone marrow (ATBM) cells were prepared by ﬂushing bone
marrow cells from the femurs of donor mice, followed by incubationwith J1j
(anti-thy-1.2) mAb (1:100 dilution) and guinea pig complement (C0) (1:5) for
45 minutes at 37C. T celleenriched donor cell populations were prepared
from pooled RBC-lysed spleen cell suspensions. B cells were removed by
incubation with J11D2 mAb (1:500) and C0 for 45 minutes at 37C. B6C3F1
host animals were exposed to 1100 cGy irradiation (split dose of
550 cGy  2, 4 hours apart) using a 137Ce source (Gammacell 40 Exactor;
MDS Nordion, Ottawa, Ontario, Canada). Within 3 to 4 hours after irradiation
was completed, the mice were transplanted via tail vein injection with
2  106 C3H ATBM cells. For GVHD induction, mice simultaneously received5106 C3H splenic enriched Tcells. Mice were weighed twice per week and
evaluated daily for clinical signs, including mobility, activity, hunching,
grooming, diarrhea (during observation and handling), loss of fur, and skin
lesions. Weight loss up to 30% of initial weight was permitted if mice
remained active, because these animals often survived and recovered some
or all of the lost weight over the observation period.
Fasudil Treatment
Fasudil-treated mice started the drug 24 hours before irradiation and
transplant, receiving both i.p. (fasudil-hydrochloride, 200 mg twice daily)
and p.o. (fasudil-dihydrochloride, 1 mg/mL drinking water, orw3 mg/day).
This dual mode of administration was continued for 10 days post-
transplantation, after which time i.p. injections were discontinued but p.o.
drug was maintained for the period of observation (up to 90 days).
In Vitro Assays
IFN-g ELISpot
Spleens from mice 10 days post-transplantation were homogenized to
single-cell suspensions, pooled, and cultured at 1 107 responder cells with
1 107 irradiated (3000 cGy) stimulator cells in 2 mL for 4 days. Cells were
washed and plated at 2  105 overnight in triplicate on nitrocellulose EIA
plates coated with rat anti-mouse IFN-g mAb (50 mg/mL), developed with
biotinylated rat anti-mouse IFN-g (4 mg/mL), and ELISpots scored by an
automated Cellular Technology Limited Immunospot Series 3A reader
(Shaker Heights, OH).
Carboxyﬂuorescein succinimidyl ester proliferation
in one-way mixed lymphocyte reactions
Twelve  106 splenocytes from B6C3F1 hosts were harvested at day 98
post-transplantation, labeledwith CFSE (5 mM), andmixed at a 3:1 responder-
to-stimulator ratio with unlabeled 3000 cGy irradiated B6C3F1, C3H, or
BALB/c splenocytes. Cells were recovered and assayed for CFSE intensity
peaks using a ﬂow cytometer (model FC500; Beckman Coulter, Brea, CA).
Histopathology
Long-term survivor mice (12 to 13 weeks post-transplant) were killed
and immediately dissected to remove liver, spleen, lung, tongue, and small
intestines. Tongue was used as a substitute for skin, because it is much
easier to prepare for histology and typically reﬂects the events simulta-
neously occurring in the dermis. Tissue was sliced into 2- to 5-mm sec-
tions, washed with PBS, and cryopreserved in optimal cutting temperature
medium (VWR Scientiﬁc, Radnor, PA) freezing media in molds ﬂoating in
liquid nitrogen. After 10 minutes, frozen samples were transferred to
e80oC and stored for subsequent thin sectioning and staining with H & E.
Slides were scored using a published grading system [31] for focal or
diffuse inﬁltration of inﬂammatory leuokocytes into lamina propria,
crypts, with or without destruction of crypt and villous architecture: 0,
rare inﬂammatory cells in the lamina propria; 1, increased numbers of
granulocytes in the lamina propria; 2, conﬂuence of inﬂammatory cells
extending into the submucosa; 3, transmural extension of the inﬂamma-
tory inﬁltrate. Crypt damage was scored as follows: 0, intact crypts; 1, loss
of the basal one-third; 2, loss of the basal two-thirds; 3, entire crypt loss;
4, change of epithelial surface with erosion; 5, conﬂuent erosion. Ulcera-
tion was scored as follows: 0, absence of ulcer; 1, 1 or 2 foci of ulcerations;
2, 3 or 4 foci of ulcerations; 3, conﬂuent or extensive ulceration. Values
were added to give a maximal histological score of 11.
Statistics
Survival curves were estimated using Kaplan-Meier’s product limit
method. Comparison of survival curves was performed using a 2-sided log-
rank test. Comparisons of treatment group weights over time were made
using the nonparametric Kolmogorov-Smirnov test, with no a priori
assumption of normal distribution. Proportions were compared by a 2-sided
z test for signiﬁcant differences. Survival data analysis was performed using
SAS 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Survival
As shown in Figure 1, fasudil-treated B6C3F1 mice had
signiﬁcantly greater 90-day survival after injection of C3H
ATBM þ T cells compared with untreated recipients (73%
versus 25%, P< .0001). In the GVHD control group, most mice
(70%) succumbed to disease between days 8 and 28 post-
transplantation. In the fasudil-treated group, most fatalities
Figure 1. Fasudil decreases mortality from GVHD. Fasudil administered i.p. for 10 days and in drinking water for the duration of the experiment starting 1 day before
lethal irradiation and transfer of ATBM þ donor T cells signiﬁcantly increased 90-day survival from 25% to 73% (P < .0001). Irradiated mice not receiving donor cells
showed different early survival rates, with all deaths occurring within a relatively narrow window of 12 to 16 days. Data were pooled from 3 separate replicate
experiments involving total sample sizes of 10 to 26 for the different groups, as indicated.
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8 to 18), and only 2 additional deaths occurred later, between
days 47 and 56. As expected, mice transplanted with only
C3H ATBM cells all survived, and mice exposed to lethal
irradiation alone without receiving any donor ATBM cells
succumbed within a narrow window, 12 to 16 days
post-irradiation.
Weight Loss
With or without fasudil treatment, ATBM þ T mice
experienced signiﬁcant weight loss within the ﬁrst 2 weeks
(25% to 30%) compared with ATBM-only recipients (10%). On
average, fasudil-treated and untreated surviving mice lost
the same percentage of weight in the ﬁrst 1 to 2 weeks, with
comparable kinetics of weight stabilization and gradual in-
crease among 1-month survivors. There was continued
gradual, but incomplete, weight recovery over the remaining
period of observation (Figure 2). Among these progressively
more self-selected animals in both groups surviving beyond
day 28, weight recovery of fasudil-treated mice was signiﬁ-
cantly greater than among untreated mice receiving
ATBM þ T cells (P ¼ .001).
Irradiated mice receiving no stem cell replacement
closely matched the weight curve of ATBM transplants for
the ﬁrst 7 days, losing only 10% of starting weight rather than
the 25% to 30% lost by mice receiving ATBM þmature donor
T cells. However, although the latter groups stabilized or
gradually increased their weights during the second and
subsequent weeks post-transplant, the irradiated, untrans-
planted animals continued to lose weight, before dying
between days 12 and 16.
Diarrhea
Despite the similar weight losses among fasudil-treated
and untreated T cell recipients in the ﬁrst 2 weeks, the 2groups had different rates of diarrhea. Most untreated mice
(>70%) had loose stools for 1 or more days between the
second and third weeks post-transplantation, the period of
highest mortality incidence. By comparison, less than 20% of
the fasudil-treated mice developed clinically observable
diarrhea during that time. Diarrhea resolved by the fourth
week among survivors in both groups. Irradiated mice not
receiving donor cells were not observed to have diarrhea
before death.Gut Histopathology
H & E staining of tissue sections from long-term survivors
of fasudil-treated or untreated groups showedminimal or no
inﬂammation of small intestines, liver, spleen, or tongue.
Figure 3A shows the normal histology of gut crypts and villi
seen in most sections among 5 fasudil-treated mice killed
90 days post-transplant. In 3 of 5 mice examined, moderate
inﬂammatory cell inﬁltrates were seen at the base of the
crypts in some sections, but crypt and villous architecture
was intact (Figure 3B), giving an overall score of only 2/11 in
the most severe cases. Of the 3 untreated long-term survi-
vors killed for histopathology, none exhibited even mild
inﬂammation of the sampled tissues in any of the examined
sections (scoring 0/11).Spleen Size
A suggestion of modest non-IT protectionwas the roughly
50% increase in day 90 spleen cellularity among fasudil-
treated (3.6  106 per spleen) versus untreated (2.2  106
per spleen) mice receiving mature donor T cells. However,
both groups had greatly reduced splenocyte counts (roughly
7% versus 4%, respectively) compared with ATBM-only re-
cipients’ spleens, which contained approximately 5  107
cells per spleen.
Figure 2. Fasudil does not fully prevent weight loss during acute GVHD. Despite impressive reduction in mortality, mice receiving fasudil along with ATBM þ donor
T cells were not spared signiﬁcant weight loss, comparable with untreated ATBM þ T recipients, during the ﬁrst month post-transplantation. In the ﬁrst week, these
groups lost 2 to 3 times as much weight as did ATBM only recipients or as irradiated mice receiving no donor cells. Fasudil-treated mice surviving the ﬁrst month of
ATBM þ T cell transplantation, as well as far fewer untreated surviving mice, gradually gained back more of their lost weight than the fewer surviving untreated mice
(P ¼ .001), but never caught up with the ATBM-only group (P < .0001).
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Despite the better survival outcome and decreased diar-
rhea, all fasudil-treated mice lost hair and developed grossly
observable skin inﬂammation and ulceration with similar
frequency and time course as untreated animals within each
experiment, starting at week 2 and resolving by week 8 (not
shown). Again, as for weight recovery, skin lesion resolution
by week 8 applied to the subset of animals from both groups
surviving through week 8, comprised mostly of animals
subsequently found to be long-term survivors.
Systemic Alloreactivity
Persistent skin involvement, weight loss, and only a very
modest increase in spleen cellularity suggested that neither
systemic host-speciﬁc allotolerance nor profound immuno-
suppression was the basis for fasudil’s beneﬁcial impact on
GVHD mortality. To directly address the issue of systemic
alloreactivity to host MHC molecules, we harvested spleen
cells 10 days after transplantation, the earliest time point at
which donor T cells were recoverable in sufﬁcient numbers
from host spleens, and, at the other extreme, after the ﬁnal
week of observation (day 98 post-transplantation). Table 1
presents data for day 10 splenic lymphocytes, which reﬂect
only donor T cells, because no stem or progenitor cell-
derived T cells emigrating from the host thymus are pre-
sent in host spleens at this time point. As shown, there was
no evidence of fasudil-induced allotolerance to host MHC, as
measured by IFN-g ELISpot after 1-way donor C3H versus
irradiated B6C3F1 stimulation of splenocytes in vitro. Early
time point donor-derived T cells responded at least as
robustly as splenocytes from untreated mice. Indeed, the
greater response to B6 parental MHC alloantigens than to
third party DBA/2 (H2d) alloantigens suggested possible
in vivo priming within the B6C3F1 hosts. As expected,
spleens from mice receiving no mature donor T cells (ATBMonly) made no responses to any of the stimuli, because no
newly formed T cells had yet emerged from the thymus and
migrated to the spleen.
Spleens from day 98 survivor mice had many more lym-
phocytes, allowing CFSE labeling of pooled spleen cells with
ﬂow-based assessment of cell division (dilutional peaks) in
response to alloantigen recognition. Figure 4 shows that
CFSE-labeled splenic lymphocytes from B6C3F1 recipients of
ATBM cells alone had a relatively low proportion of cells
undergoing multiple rounds of division after 5 days of
stimulation with irradiated host cells (Figure 4A), compared
with the proportion of cells undergoing multiple rounds of
division in response to third-party allogeneic BALB/c stimu-
lators (Figure 4B). The limited response to parental B6 MHC
antigens is expected from C3H stem cellederived T cells
generated de novo within the F1 host thymic environment.
By contrast, splenocytes from recipients of ATBM þ donor
T cells made a much stronger response to B6C3F1 cell stim-
ulation (Figure 4C), very similar in magnitude to their
response to BALB/c stimulation (Figure 4D). Fasudil-treated
recipients of ATBM þ T cells also contained splenocytes
that made a strong response to B6C3F1 stimulation, with
multiple rounds of cell division that yielded weakly ﬂuo-
rescent peaks (Figure 4E), comparable to their response to
BALB/c stimulation (Figure 4F).
DISCUSSION
Loss of alloreactive GVT effect is the main drawback of
purging mature T cells from the donor graft to avoid GVHD
development after HCT. In theory, protecting the most
vulnerable target organs from lethal GVHD, while maintain-
ing systemic antihost alloreactivity, at least during the early
post-transplantation period, might reduce NRM and still
allowefﬁcient elimination of residual tumor by cell-mediated
effector mechanisms directed at host alloantigens. Through
Figure 3. Long-term fasudil-treated and untreated survivors of GVHD have
minimal inﬂammation of sampled tissues. Most small bowel sections from
fasudil-treated animals showed normal architecture of crypts and villi,
without evidence of inﬂammation (A). In 3 of 5 animals, scattered areas of
lamina propria and basilar crypt inﬂammation were seen (dashed white lines),
with no disruption of the crypt or villous architecture (B). No inﬂammation
was observed in multiple samples taken from 3 untreated surviving animals
(not shown).
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previous mouse studies suggested the feasibility of such an
approach [12e16]. Moreover, monoclonal antibodies to gut
homing lymphocyte surface receptors ameliorated GVHD,
and, in the case of anti-a4b7, GVT effects were shown to
remain intact [12]. A less organ speciﬁc, systemic inhibition of
CTL PKCa and PKCq proteins also prevented GVHD and leftTable 1
Day 10 IFN-g Secreting Spleen Cell Frequencies after 5-Day One-Way Mixed
Lymphocyte Reactions versus Self (C3H), Host B6C3F1, or Third-Party (DBA/
2, H2d) Stimulators
Irradiated
Stimulators
Responding Splenocytes (per 2  105 cells) from
Hosts Receiving:
ATBM
Only
ATBM þ T
Cells
ATBM þ T
Cells þ Fasudil
C3H 0 4.6 2.3
B6C3F1 0 82.3 115.6
DBA/2 (H2d) 0 16.0 18.0
Con A 1 61.3 120.0
At this early time point, only donor mature T cells are present and show no
evidence of general immune suppression or tolerance for host B6 parental
derived MHC alloantigens in fasudil-treated animals. Differences between
ATBM-only and ATBM þ T cell hosts, with or without fasudil treatment,
were signiﬁcant for all stimulations (P < .001).some alloreactivity intact, with the GVT effect not detectably
diminished [13].
In humans, a trial of the CCR5 antagonist, maraviroc,
from e2 to þ30 days post-HCT resulted in dramatically
reduced acute GVHD and NRM for at least 1 year post-
transplantation, compared with historical control subjects
at the same institution [5]. In particular, there was no grade
III or IV IT or liver acute GVHD. Thus, a relatively short
course of treatment during the initial period of trans-
plantation appeared sufﬁcient to alter the subsequent
course of GVHD for at least 1 year. The 20% increase in
cancer relapse observed (56% versus 46% in recent historic
control subjects from the same institution) did not reach
statistical signiﬁcance but did raise concerns regarding the
possibility that inhibition of CCR5 might interfere with GVT
effects [32].
On the other hand, the lack of a much more dramatic
increase in relapse after early and brief CCR5 blockade is
consistent with a retrospective analysis that found a strong
inverse correlation of recurrent cancer with chronic GVHD
but not acute GVHD [6]. Furthermore, CCR5 has been iden-
tiﬁed as a stronger marker of gut-homing [33] than skin-
alloreactive cells [34] during the acute phase of GVHD in
humans, and IT GVHD is more lethal than skin GVHD. If these
ﬁndings hold up in further studies, they would give impetus
to the idea that inhibition of IT acute GVHD by early, short-
term immunomodulation is beneﬁcial for reducing NRM
without eliminating a GVT effect. The addition of a second
agent, such as fasudil, with protective effects against IT GVHD
might allow for dose sparing or a shortened course of mar-
aviroc, thereby maintaining suppression of lethal GVHDwith
even less chance of relapse.
The results presented herein support the concept of
protecting GVHD targeted IT organs while maintaining sys-
temic antihost alloreactivity and, consequently, a GVT effect.
Amelioration of diarrhea and ongoing recovery of lost weight
suggests IT protection by fasudil. The early death of more
severely affected mice before their weights could fall sufﬁ-
ciently to inﬂuence group averages almost certainly masked
a more dramatic treatment impact. It is likely that the p.o.
and i.p. administration of fasudil contributed to targeting the
IT for protection against the effects of inﬂammatory cyto-
kines and cytotoxic alloreactive T cells. These results do not
elucidate mechanisms, except to rule out general allotol-
erance or immune suppression. It is possible that IT vascular
endothelia permeability is more sensitive to rho kinase in-
hibition than vascular endothelia in the spleen or skin,
thereby allowing more effective inhibition of inﬂammatory
cell egress into the gut mucosa as compared with skin.
Localized generation and/or targeting of Tregs and myeloid-
derived suppressor cells is also a possibility.
Fasudil inhibition of rho-associated coiled coil kinase tar-
gets several functions that are critical for IT mucosal inﬂam-
mation: Leukocyte movement along endothelial receptors
is reduced [28,35e37], as are cell polarization and uropod
formation [21,35,38e41] and diapedesis [35,39e43]dall
required for penetration of endothelial intercellular junc-
tions. Fasudil’s protective effects on the endothelium are
complimentary. Tight junction integrity and impermeability
are increased [23,44e48], making it more difﬁcult for cells to
create intercellular gaps through which to cross the endo-
thelium. Additionally, fasudil may improve oxygenation
within the IT mucosa, because inhibition of rho-associated
coiled coil kinase increases eNOS activity, leading to NO
mediated dilation of the gut microvasculature [49,50].
Figure 4. CFSE dilution peak determination of spleen cell alloreactivity in 1-way mixed lymphocyte reactions (responder versus irradiated stimulator). Pooled
splenocytes from mice 98 days after receiving C3H donor anti-thy-1 treated bone marrow only (ATBM) made some proliferative response to host B6C3F1 cells (A).
Roughly 11% of cells divided once, and 17% divided more than once, which is expected as a consequence of normal responses to self-restricted foreign environmental
antigens. More cells (40% versus 17%, P < .001) responded with 2 or more cell divisions when third-party BALB/c cells were used as stimulators (B). By contrast, spleen
cells from mice receiving mature donor T cells along with ATBM made a strong response to host B6C3F1 cell stimulation, with w7% dividing once and w31% more
than once (C), not signiﬁcantly different from their response (8% and 32%, respectively) to BALB/c (D), but signiﬁcantly greater than (A) ATBM anti-F1 responses
(P < .001). Mice receiving fasudil, along with donor T cells and ATBM (E), also made a stronger alloresponse to B6C3F1 host cells than mice receiving only ATBM (A),
with 20% dividing once and 21% dividing more than once. Although these proportions both differ signiﬁcantly (P < .001) from the respective proportions of cells from
the untreated mice (C), they are still greater in both cases than the corresponding peaks in ATBM-only spleen cultures (P < .001) and, compared with (C), also have a
population of cells undergoing additional rounds of alloreactive division (lowest signal intensity peak). Fasudil-treated mice also retained strong anti-BALB/c MHC
responses (F), with a peak proﬁle roughly similar in distribution to (E). Data are representative of 2 replicate experiments and 4 culture time points.
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(VEGF) antagonism [39,51], could decrease hypoxia driven
neovascularization [52e55], which has been found to be a
hallmark of IT GVHD [13,14].
Hypoxia has been associated with Treg induction, espe-
cially in the context of tumor growth [56e69], so alleviation
of hypoxia by fasudil would not be expected to directly favor
the development of IT Tregs. On the other hand, immuno-
tolerance is the default setting of the healthy IT, with a
dominant effect of Tregs suppressing the response to most
antigens of gut origin. Most of the body’s vitamin A is within
fat-storing hepatic stellate cells that, in the presence of
vitamin Aederived retinoic acid and TGF-b, induce Ag-
speciﬁc Tregs directly or induce resident myeloid-derived
suppressor cells to generate Tregs [70] that home back to
liver and IT. To the extent that fasudil helps to maintain andrestore a relatively normal IT and liver microenvironment, it
may favor the default generation of Tregs.
Identifying the various mechanisms of action for fasudil
protection against GVHD and demonstrating preservation of
alloreactive GVT effect support a shift in the paradigm of
GVHD treatment away from systemic immunosuppression
and toward organ targeted protection. In combination with
1 or more agents discussed above, fasudil could become a
mainstay of GVHD prophylaxis and treatment in the setting
of allogeneic HCT. Clinical translation should be facilitated
by the drug’s excellent safety proﬁle during 2 decades of
clinical use for prevention of poststroke cerebral spasm
[29,30].
There is room for improvementwith the fasudil approach.
First, one-fourth of the treated animals still succumbed to
GVHD, including some during initial i.p. treatment, with an
S. Iyengar et al. / Biol Blood Marrow Transplant 20 (2014) 1104e11111110incidence indistinguishable from the untreated group for the
ﬁrst 8 days. Second, treated surviving mice experienced se-
vere weight loss for the initial 2 weeks, similar to that seen
among untreated animals. Third, splenocytes from treated,
long-term survivors were dramatically reduced in number
compared with ATBM-only recipients. Fourth, the skin
remained a major site of GVHD in animals receiving fasudil
via the i.p. and p.o. routes, although all surviving mice
resolved their skin lesions. Skin GVHD is a major cause of
morbidity in patients. Topical fasudil may eventually be
useful in treating persistent skin targeted GVHD.
Finally, it is worth noting that, other than improved
weight gain, the grossly observable, histopathological, and
immunological phenotype of fasudil-treated long-term sur-
vivors is largely indistinguishable from the much less
frequent untreated long-term survivors. That is, fasudil ap-
pears to foster a series of events favoring organ selective
tolerance or resistance, which also occurs naturally in some
untreated animals. The details of this protective process
remain to be elucidated, but the observation suggests that
short-term treatments, with other agents having different
proximate mechanisms of action, such as those mentioned
above, may be combined with fasudil to generate potent,
dose-sparing regimens.
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